ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Vaccine Particulate Adjuvants Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-18L9915
Home | Market Reports | Law & Government| Public Safety
Global Vaccine Particulate Adjuvants Market Insights Forecast to 2028
BUY CHAPTERS

Global Vaccine Particulate Adjuvants Market Research Report 2025

Code: QYRE-Auto-18L9915
Report
January 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Brenntag Biosector (Denmark)
CSL Limited (Australia)
SEPPIC (France)
Agenus, Inc (US)
Novavax, Inc (US)
SPI Pharma, Inc (US)
InvivoGen (US)
Avanti Polar Lipids, Inc (US)
MVP Laboratories, Inc (US)
OZ Biosciences (France)

Vaccine Particulate Adjuvants Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Vaccine Particulate Adjuvants Market

Vaccine Particulate Adjuvants Market

The global market for Vaccine Particulate Adjuvants was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Vaccine Particulate Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccine Particulate Adjuvants.
The Vaccine Particulate Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vaccine Particulate Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vaccine Particulate Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Vaccine Particulate Adjuvants Market Report

Report Metric Details
Report Name Vaccine Particulate Adjuvants Market
CAGR 5%
Segment by Type
Segment by Application
  • Infectious Diseases
  • Cancer
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc (US), Novavax, Inc (US), SPI Pharma, Inc (US), Invivogen (US), Avanti Polar Lipids, Inc (US), MVP Laboratories, Inc (US), OZ Biosciences (France)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Vaccine Particulate Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Vaccine Particulate Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Vaccine Particulate Adjuvants Market report?

Ans: The main players in the Vaccine Particulate Adjuvants Market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc (US), Novavax, Inc (US), SPI Pharma, Inc (US), Invivogen (US), Avanti Polar Lipids, Inc (US), MVP Laboratories, Inc (US), OZ Biosciences (France)

What are the Application segmentation covered in the Vaccine Particulate Adjuvants Market report?

Ans: The Applications covered in the Vaccine Particulate Adjuvants Market report are Infectious Diseases, Cancer, Others

What are the Type segmentation covered in the Vaccine Particulate Adjuvants Market report?

Ans: The Types covered in the Vaccine Particulate Adjuvants Market report are Oral, Subcutaneous, Intranasal, Intramuscular, Intradermal, Others

Recommended Reports

Vaccine Market Overview

Inactivated & Influenza Vaccines

Specialty & Comb. Vaccines

1 Vaccine Particulate Adjuvants Market Overview
1.1 Product Definition
1.2 Vaccine Particulate Adjuvants by Type
1.2.1 Global Vaccine Particulate Adjuvants Market Value Comparison by Type (2024 VS 2031)
1.2.2 Oral
1.2.3 Subcutaneous
1.2.4 Intranasal
1.2.5 Intramuscular
1.2.6 Intradermal
1.2.7 Others
1.3 Vaccine Particulate Adjuvants by Application
1.3.1 Global Vaccine Particulate Adjuvants Market Value by Application (2024 VS 2031)
1.3.2 Infectious Diseases
1.3.3 Cancer
1.3.4 Others
1.4 Global Vaccine Particulate Adjuvants Market Size Estimates and Forecasts
1.4.1 Global Vaccine Particulate Adjuvants Revenue 2020-2031
1.4.2 Global Vaccine Particulate Adjuvants Sales 2020-2031
1.4.3 Global Vaccine Particulate Adjuvants Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Vaccine Particulate Adjuvants Market Competition by Manufacturers
2.1 Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers (2020-2025)
2.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Vaccine Particulate Adjuvants Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Vaccine Particulate Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vaccine Particulate Adjuvants, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vaccine Particulate Adjuvants, Product Type & Application
2.7 Global Key Manufacturers of Vaccine Particulate Adjuvants, Date of Enter into This Industry
2.8 Global Vaccine Particulate Adjuvants Market Competitive Situation and Trends
2.8.1 Global Vaccine Particulate Adjuvants Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Vaccine Particulate Adjuvants Players Market Share by Revenue
2.8.3 Global Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vaccine Particulate Adjuvants Market Scenario by Region
3.1 Global Vaccine Particulate Adjuvants Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Vaccine Particulate Adjuvants Sales by Region: 2020-2031
3.2.1 Global Vaccine Particulate Adjuvants Sales by Region: 2020-2025
3.2.2 Global Vaccine Particulate Adjuvants Sales by Region: 2026-2031
3.3 Global Vaccine Particulate Adjuvants Revenue by Region: 2020-2031
3.3.1 Global Vaccine Particulate Adjuvants Revenue by Region: 2020-2025
3.3.2 Global Vaccine Particulate Adjuvants Revenue by Region: 2026-2031
3.4 North America Vaccine Particulate Adjuvants Market Facts & Figures by Country
3.4.1 North America Vaccine Particulate Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Vaccine Particulate Adjuvants Sales by Country (2020-2031)
3.4.3 North America Vaccine Particulate Adjuvants Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Vaccine Particulate Adjuvants Market Facts & Figures by Country
3.5.1 Europe Vaccine Particulate Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Vaccine Particulate Adjuvants Sales by Country (2020-2031)
3.5.3 Europe Vaccine Particulate Adjuvants Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vaccine Particulate Adjuvants Market Facts & Figures by Region
3.6.1 Asia Pacific Vaccine Particulate Adjuvants Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Vaccine Particulate Adjuvants Sales by Region (2020-2031)
3.6.3 Asia Pacific Vaccine Particulate Adjuvants Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Vaccine Particulate Adjuvants Market Facts & Figures by Country
3.7.1 Latin America Vaccine Particulate Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Vaccine Particulate Adjuvants Sales by Country (2020-2031)
3.7.3 Latin America Vaccine Particulate Adjuvants Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vaccine Particulate Adjuvants Market Facts & Figures by Country
3.8.1 Middle East and Africa Vaccine Particulate Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2020-2031)
3.8.3 Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Vaccine Particulate Adjuvants Sales by Type (2020-2031)
4.1.1 Global Vaccine Particulate Adjuvants Sales by Type (2020-2025)
4.1.2 Global Vaccine Particulate Adjuvants Sales by Type (2026-2031)
4.1.3 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2020-2031)
4.2 Global Vaccine Particulate Adjuvants Revenue by Type (2020-2031)
4.2.1 Global Vaccine Particulate Adjuvants Revenue by Type (2020-2025)
4.2.2 Global Vaccine Particulate Adjuvants Revenue by Type (2026-2031)
4.2.3 Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2020-2031)
4.3 Global Vaccine Particulate Adjuvants Price by Type (2020-2031)
5 Segment by Application
5.1 Global Vaccine Particulate Adjuvants Sales by Application (2020-2031)
5.1.1 Global Vaccine Particulate Adjuvants Sales by Application (2020-2025)
5.1.2 Global Vaccine Particulate Adjuvants Sales by Application (2026-2031)
5.1.3 Global Vaccine Particulate Adjuvants Sales Market Share by Application (2020-2031)
5.2 Global Vaccine Particulate Adjuvants Revenue by Application (2020-2031)
5.2.1 Global Vaccine Particulate Adjuvants Revenue by Application (2020-2025)
5.2.2 Global Vaccine Particulate Adjuvants Revenue by Application (2026-2031)
5.2.3 Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2020-2031)
5.3 Global Vaccine Particulate Adjuvants Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Brenntag Biosector (Denmark)
6.1.1 Brenntag Biosector (Denmark) Company Information
6.1.2 Brenntag Biosector (Denmark) Description and Business Overview
6.1.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio
6.1.5 Brenntag Biosector (Denmark) Recent Developments/Updates
6.2 CSL Limited (Australia)
6.2.1 CSL Limited (Australia) Company Information
6.2.2 CSL Limited (Australia) Description and Business Overview
6.2.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.2.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio
6.2.5 CSL Limited (Australia) Recent Developments/Updates
6.3 SEPPIC (France)
6.3.1 SEPPIC (France) Company Information
6.3.2 SEPPIC (France) Description and Business Overview
6.3.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.3.4 SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio
6.3.5 SEPPIC (France) Recent Developments/Updates
6.4 Agenus, Inc (US)
6.4.1 Agenus, Inc (US) Company Information
6.4.2 Agenus, Inc (US) Description and Business Overview
6.4.3 Agenus, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Agenus, Inc (US) Vaccine Particulate Adjuvants Product Portfolio
6.4.5 Agenus, Inc (US) Recent Developments/Updates
6.5 Novavax, Inc (US)
6.5.1 Novavax, Inc (US) Company Information
6.5.2 Novavax, Inc (US) Description and Business Overview
6.5.3 Novavax, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novavax, Inc (US) Vaccine Particulate Adjuvants Product Portfolio
6.5.5 Novavax, Inc (US) Recent Developments/Updates
6.6 SPI Pharma, Inc (US)
6.6.1 SPI Pharma, Inc (US) Company Information
6.6.2 SPI Pharma, Inc (US) Description and Business Overview
6.6.3 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.6.4 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Product Portfolio
6.6.5 SPI Pharma, Inc (US) Recent Developments/Updates
6.7 Invivogen (US)
6.7.1 Invivogen (US) Company Information
6.7.2 Invivogen (US) Description and Business Overview
6.7.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio
6.7.5 Invivogen (US) Recent Developments/Updates
6.8 Avanti Polar Lipids, Inc (US)
6.8.1 Avanti Polar Lipids, Inc (US) Company Information
6.8.2 Avanti Polar Lipids, Inc (US) Description and Business Overview
6.8.3 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Product Portfolio
6.8.5 Avanti Polar Lipids, Inc (US) Recent Developments/Updates
6.9 MVP Laboratories, Inc (US)
6.9.1 MVP Laboratories, Inc (US) Company Information
6.9.2 MVP Laboratories, Inc (US) Description and Business Overview
6.9.3 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.9.4 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Product Portfolio
6.9.5 MVP Laboratories, Inc (US) Recent Developments/Updates
6.10 OZ Biosciences (France)
6.10.1 OZ Biosciences (France) Company Information
6.10.2 OZ Biosciences (France) Description and Business Overview
6.10.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.10.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio
6.10.5 OZ Biosciences (France) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vaccine Particulate Adjuvants Industry Chain Analysis
7.2 Vaccine Particulate Adjuvants Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vaccine Particulate Adjuvants Production Mode & Process Analysis
7.4 Vaccine Particulate Adjuvants Sales and Marketing
7.4.1 Vaccine Particulate Adjuvants Sales Channels
7.4.2 Vaccine Particulate Adjuvants Distributors
7.5 Vaccine Particulate Adjuvants Customer Analysis
8 Vaccine Particulate Adjuvants Market Dynamics
8.1 Vaccine Particulate Adjuvants Industry Trends
8.2 Vaccine Particulate Adjuvants Market Drivers
8.3 Vaccine Particulate Adjuvants Market Challenges
8.4 Vaccine Particulate Adjuvants Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Brenntag Biosector (Denmark)
CSL Limited (Australia)
SEPPIC (France)
Agenus, Inc (US)
Novavax, Inc (US)
SPI Pharma, Inc (US)
InvivoGen (US)
Avanti Polar Lipids, Inc (US)
MVP Laboratories, Inc (US)
OZ Biosciences (France)
List of Tables
 Table 1. Global Vaccine Particulate Adjuvants Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Vaccine Particulate Adjuvants Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Vaccine Particulate Adjuvants Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Vaccine Particulate Adjuvants Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Vaccine Particulate Adjuvants Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Vaccine Particulate Adjuvants Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Vaccine Particulate Adjuvants Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Vaccine Particulate Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Vaccine Particulate Adjuvants, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Vaccine Particulate Adjuvants, Product Type & Application
 Table 12. Global Key Manufacturers of Vaccine Particulate Adjuvants, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Vaccine Particulate Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine Particulate Adjuvants as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Vaccine Particulate Adjuvants Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Vaccine Particulate Adjuvants Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2020-2025)
 Table 19. Global Vaccine Particulate Adjuvants Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2026-2031)
 Table 21. Global Vaccine Particulate Adjuvants Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2020-2025)
 Table 23. Global Vaccine Particulate Adjuvants Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2026-2031)
 Table 25. North America Vaccine Particulate Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Vaccine Particulate Adjuvants Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Vaccine Particulate Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Vaccine Particulate Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Vaccine Particulate Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Vaccine Particulate Adjuvants Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Vaccine Particulate Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Vaccine Particulate Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Vaccine Particulate Adjuvants Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Vaccine Particulate Adjuvants Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Vaccine Particulate Adjuvants Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Vaccine Particulate Adjuvants Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Vaccine Particulate Adjuvants Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Vaccine Particulate Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Vaccine Particulate Adjuvants Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Vaccine Particulate Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Vaccine Particulate Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2020-2025)
 Table 53. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2026-2031)
 Table 54. Global Vaccine Particulate Adjuvants Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Vaccine Particulate Adjuvants Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2020-2025)
 Table 57. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2026-2031)
 Table 58. Global Vaccine Particulate Adjuvants Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Vaccine Particulate Adjuvants Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2020-2025)
 Table 63. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2026-2031)
 Table 64. Global Vaccine Particulate Adjuvants Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Vaccine Particulate Adjuvants Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2020-2025)
 Table 67. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2026-2031)
 Table 68. Global Vaccine Particulate Adjuvants Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Vaccine Particulate Adjuvants Price (USD/Pcs) by Application (2026-2031)
 Table 70. Brenntag Biosector (Denmark) Company Information
 Table 71. Brenntag Biosector (Denmark) Description and Business Overview
 Table 72. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product
 Table 74. Brenntag Biosector (Denmark) Recent Developments/Updates
 Table 75. CSL Limited (Australia) Company Information
 Table 76. CSL Limited (Australia) Description and Business Overview
 Table 77. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. CSL Limited (Australia) Vaccine Particulate Adjuvants Product
 Table 79. CSL Limited (Australia) Recent Developments/Updates
 Table 80. SEPPIC (France) Company Information
 Table 81. SEPPIC (France) Description and Business Overview
 Table 82. SEPPIC (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. SEPPIC (France) Vaccine Particulate Adjuvants Product
 Table 84. SEPPIC (France) Recent Developments/Updates
 Table 85. Agenus, Inc (US) Company Information
 Table 86. Agenus, Inc (US) Description and Business Overview
 Table 87. Agenus, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Agenus, Inc (US) Vaccine Particulate Adjuvants Product
 Table 89. Agenus, Inc (US) Recent Developments/Updates
 Table 90. Novavax, Inc (US) Company Information
 Table 91. Novavax, Inc (US) Description and Business Overview
 Table 92. Novavax, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Novavax, Inc (US) Vaccine Particulate Adjuvants Product
 Table 94. Novavax, Inc (US) Recent Developments/Updates
 Table 95. SPI Pharma, Inc (US) Company Information
 Table 96. SPI Pharma, Inc (US) Description and Business Overview
 Table 97. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Product
 Table 99. SPI Pharma, Inc (US) Recent Developments/Updates
 Table 100. Invivogen (US) Company Information
 Table 101. Invivogen (US) Description and Business Overview
 Table 102. Invivogen (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Invivogen (US) Vaccine Particulate Adjuvants Product
 Table 104. Invivogen (US) Recent Developments/Updates
 Table 105. Avanti Polar Lipids, Inc (US) Company Information
 Table 106. Avanti Polar Lipids, Inc (US) Description and Business Overview
 Table 107. Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Product
 Table 109. Avanti Polar Lipids, Inc (US) Recent Developments/Updates
 Table 110. MVP Laboratories, Inc (US) Company Information
 Table 111. MVP Laboratories, Inc (US) Description and Business Overview
 Table 112. MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Product
 Table 114. MVP Laboratories, Inc (US) Recent Developments/Updates
 Table 115. OZ Biosciences (France) Company Information
 Table 116. OZ Biosciences (France) Description and Business Overview
 Table 117. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. OZ Biosciences (France) Vaccine Particulate Adjuvants Product
 Table 119. OZ Biosciences (France) Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Vaccine Particulate Adjuvants Distributors List
 Table 123. Vaccine Particulate Adjuvants Customers List
 Table 124. Vaccine Particulate Adjuvants Market Trends
 Table 125. Vaccine Particulate Adjuvants Market Drivers
 Table 126. Vaccine Particulate Adjuvants Market Challenges
 Table 127. Vaccine Particulate Adjuvants Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Vaccine Particulate Adjuvants
 Figure 2. Global Vaccine Particulate Adjuvants Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Vaccine Particulate Adjuvants Market Share by Type: 2024 & 2031
 Figure 4. Oral Product Picture
 Figure 5. Subcutaneous Product Picture
 Figure 6. Intranasal Product Picture
 Figure 7. Intramuscular Product Picture
 Figure 8. Intradermal Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Vaccine Particulate Adjuvants Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Vaccine Particulate Adjuvants Market Share by Application: 2024 & 2031
 Figure 12. Infectious Diseases
 Figure 13. Cancer
 Figure 14. Others
 Figure 15. Global Vaccine Particulate Adjuvants Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Vaccine Particulate Adjuvants Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Vaccine Particulate Adjuvants Sales (2020-2031) & (K Pcs)
 Figure 18. Global Vaccine Particulate Adjuvants Average Price (USD/Pcs) & (2020-2031)
 Figure 19. Vaccine Particulate Adjuvants Report Years Considered
 Figure 20. Vaccine Particulate Adjuvants Sales Share by Manufacturers in 2024
 Figure 21. Global Vaccine Particulate Adjuvants Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Vaccine Particulate Adjuvants Players: Market Share by Revenue in Vaccine Particulate Adjuvants in 2024
 Figure 23. Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Vaccine Particulate Adjuvants Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Vaccine Particulate Adjuvants Sales Market Share by Country (2020-2031)
 Figure 26. North America Vaccine Particulate Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Vaccine Particulate Adjuvants Sales Market Share by Country (2020-2031)
 Figure 30. Europe Vaccine Particulate Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Vaccine Particulate Adjuvants Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Vaccine Particulate Adjuvants Revenue Market Share by Region (2020-2031)
 Figure 38. China Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Vaccine Particulate Adjuvants Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Vaccine Particulate Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Vaccine Particulate Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. U.A.E Vaccine Particulate Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Vaccine Particulate Adjuvants by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Vaccine Particulate Adjuvants by Type (2020-2031)
 Figure 60. Global Vaccine Particulate Adjuvants Price (USD/Pcs) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Vaccine Particulate Adjuvants by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Vaccine Particulate Adjuvants by Application (2020-2031)
 Figure 63. Global Vaccine Particulate Adjuvants Price (USD/Pcs) by Application (2020-2031)
 Figure 64. Vaccine Particulate Adjuvants Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Aluminum based Vaccine Adjuvant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccines Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccines Packaging Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Vaccines Market Research Report 2025
Preventable Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Penetrating Adjuvants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Administration Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Attenuated Vaccine Market Research Report 2025
Global Vaccine Digital Data Logger Market Insights Forecast to 2030
Vaccine Shippers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vaccine Cooler Market Research Report 2025
Vaccine Combinations Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prostate Cancer Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza A Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Edible Vaccine Market Research Report 2025
Global Livestock Vaccine Market Research Report 2025
Vaccine Ampoules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GP Vaccination Market Research Report 2025
Viral Vaccine Media Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions